cGAS-STING DNA-sensing in inflammatory bowel diseases

Area of Science:

• Gastroenterology and Immunology
• Molecular and Cellular Biology

Background:

• Inflammatory bowel diseases (IBD) are chronic, incurable conditions affecting millions globally.
• Pediatric-onset IBD presents with more aggressive features than adult-onset IBD, with underlying mechanisms poorly understood.
• DNA release and subsequent activation of DNA-sensing pathways, like cGAS-STING, are implicated in inflammatory colitis.

Purpose of the Study:

• To review recent advances in understanding DNA release and cGAS-STING pathway activation in IBD.
• To explore the role of the cGAS-STING pathway in the pathogenesis of inflammatory colitis.
• To discuss the therapeutic potential of targeting the cGAS-STING pathway for IBD treatment.

Main Methods:

• Literature review of experimental and human studies on IBD, DNA sensing, and the cGAS-STING pathway.
• Analysis of current knowledge on DNA sources (nuclear, mitochondrial, microbial) in IBD.
• Discussion of evidence for increased cGAS and STING expression in IBD colonic tissues.

Main Results:

• Increased colonic expression of cGAS (cyclic GMP-AMP synthase) and STING (stimulator of interferon genes) is observed in IBD.
• DNA release from damaged cells or the microbiome can activate the cGAS-STING innate immune pathway.
• This activation contributes to the inflammatory processes underlying colitis.

Conclusions:

• The cGAS-STING pathway is a key player in the inflammatory response in IBD.
• Understanding DNA release and sensor activation mechanisms is crucial for developing novel IBD therapies.
• Targeting the cGAS-STING pathway holds promise as a therapeutic strategy for inflammatory colitis.